about
ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura.Mechanisms of Autoantibody-Induced Pathology.Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.The role of platelet and endothelial GARP in thrombosis and hemostasis.Tracking down contact activation - from coagulation in vitro to inflammation in vivo.Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndromeResponse to Letter Regarding Article, “Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy”Acquired von Willebrand syndrome in patients on long-term left ventricular assist device support: Results of a Belgian centervon Willebrand factor in experimental malaria-associated acute respiratory distress syndromeClinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpuraAnti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of Pregnancy-Onset Immune-Mediated Thrombotic Thrombocytopenic PurpuraFunctional Genomics for the Identification of Modulators of Platelet-Dependent Thrombus Formation
P50
Q33427651-9C76C95A-49D3-45B5-927B-0A5DDFF8FBAAQ33437847-33000E18-CC40-408F-B600-1FFA8AC41A5CQ33740580-FF043BFA-6F81-4988-99BE-2B1C28766518Q36091783-C6384E33-CD09-43EB-83F2-6358E77C02C3Q36302394-4AA54C00-D092-4AC1-BF6D-3B9947E96EA6Q38205955-384F410D-D4A6-4A94-911A-F80D4D6B655EQ45874207-ECA54B5A-C0F7-4EAA-87D9-BD72DA53D9ADQ47693300-2F2AD2D0-96D7-468E-A99C-63A8934460B6Q52935271-10C7D5A2-6C95-4EDD-ABE4-18D22F195BDDQ58580854-6DA0D1A3-11F3-41D6-BE8D-9410DB874D4AQ58895634-1FD3999A-38AA-46E4-8C6A-192F59C8FA48Q91227310-11610007-59E4-4192-8F68-1BD64C388E34Q92112370-6CFD178E-427B-432D-BF54-295101F565B2Q93052151-6BBFABA1-5409-4871-9769-4B68F5440EC1Q93092063-5840218C-2C35-4CD5-8865-0B01F81E5173Q93092183-F08F7268-DA03-4F66-8D59-6233E8262D9E
P50
description
investigador
@es
researcher
@en
name
Claudia Tersteeg
@en
type
label
Claudia Tersteeg
@en
prefLabel
Claudia Tersteeg
@en
P31
P496
0000-0002-6380-6349